Manufacturer
MALAYSIAN PHARMACEUTICAL INDUSTRIES SDN. BHD.
Contents
Lithium carbonate 300mg
Indication
mood-stabilizing agent indicated for the treatment of manic episodes and as maintenance treatment for Bipolar I Disorder.
Instruction
300 mg to 600 mg, two to three times daily
Drug interaction
Diuretic-induced sodium loss may reduce lithium clearance and increase serum lithium concentrations. NSAID decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations. Renin-Angiotensin System Antagonists can increase steady-state serum lithium concentrations. Serotonergic Drugs can precipitate serotonin syndrome. Nitroimidazole Antibiotics may cause lithium toxicity due to reduced renal clearance. Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents can lower serum lithium concentrations by increasing urinary lithium excretion. Methyldopa, Phenytoin and Carbamazepine may increase risk of toxic effects of these drugs. Iodide Preparations may produce hypothyroidism. Calcium Channel Blocking Agents (CCB) may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. Atypical and Typical Antipsychotic Drugs in patients treated with both lithium and an antipsychotic, ranging from extrapyramidal symptoms to neuroleptic malignant syndrome, as well as reports of an encephalopathic syndrome in few patients treated with concomitant therapy, Neuromuscular Blocking Agents use may prolong the effects of neuromuscular blocking agents monitor for toxicity and prolong paralysis.
Malaysia
